HALO (STOCKS)
Halozyme Therapeutics, Inc.
$71.455000
+1.955000 (+2.81%)
Prev close: $69.500000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Helen I. Torley
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $8,475.49M
- Employees
- 350
- P/E (TTM)
- 25.00
- P/B (TTM)
- 37.50
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
9
Buy
4
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$1.60 | $1.56 | +0.0394 | +2.52% |
|
Dec 2025 (Q4)
|
$-0.24 | $2.24 | -2.4820 | -110.70% |
|
Sep 2025 (Q3)
|
$1.72 | $1.66 | +0.0591 | +3.56% |
|
Jun 2025 (Q2)
|
$1.54 | $1.29 | +0.2487 | +19.26% |
Financial Statements
| Revenues | $1.51B |
| Benefits Costs and Expenses | $1.01B |
| Cost Of Revenue | $259.61M |
| Costs And Expenses | $996.47M |
| Gross Profit | $1.25B |
| Operating Expenses | $736.86M |
| Selling, General, and Administrative Expenses | $222.61M |
| Other Operating Expenses | $503.49M |
| Operating Income/Loss | $511.99M |
| Income/Loss From Continuing Operations After Tax | $348.84M |
| Income/Loss From Continuing Operations Before Tax | $503.37M |
| Income Tax Expense/Benefit | $154.53M |
| Net Income/Loss | $348.84M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $348.84M |
| Net Income/Loss Available To Common Stockholders, Basic | $348.84M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $2.96 |
| Diluted Earnings Per Share | $2.86 |
| Basic Average Shares | 355,976,000 |
| Diluted Average Shares | 368,819,000 |
| Assets | $2.67B |
| Current Assets | $1.00B |
| Inventory | $155.47M |
| Prepaid Expenses | $75.29M |
| Other Current Assets | $772.28M |
| Noncurrent Assets | $1.67B |
| Fixed Assets | $46.93M |
| Intangible Assets | $951.96M |
| Other Non-current Assets | $670.79M |
| Liabilities | $2.45B |
| Current Liabilities | $363.21M |
| Accounts Payable | $14.10M |
| Other Current Liabilities | $349.11M |
| Noncurrent Liabilities | $2.09B |
| Equity | $219.64M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $219.64M |
| Liabilities And Equity | $2.67B |
| Net Cash Flow From Operating Activities | $677.42M |
| Net Cash Flow From Operating Activities, Continuing | $677.42M |
| Net Cash Flow From Investing Activities | -$458.27M |
| Net Cash Flow From Investing Activities, Continuing | -$458.27M |
| Net Cash Flow From Financing Activities | -$83.47M |
| Net Cash Flow From Financing Activities, Continuing | -$83.47M |
| Net Cash Flow | $135.68M |
| Net Cash Flow, Continuing | $135.68M |
| Comprehensive Income/Loss | $339.55M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $339.55M |
| Other Comprehensive Income/Loss | $339.55M |